FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support...
ANN ARBOR, Mich., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a...
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage...
MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway...
Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device DesignationNEWTOWN,...
NEW YORK and LEAMINGTON, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY;...
Meetings with Growth-Oriented Investors, September 26 to 28, 2025MISSISSAUGA, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX:...
VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed...
APOLLO BEACH, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), a pioneering developmental-stage...
Enrollment remains on track with internal interim results expected in Q2 2026Randomized study to evaluate Nociscan’s ability to improve surgical...
PALO ALTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative...
Monaghan Medical Corporation Monaghan Medical Corporation Manufacturing Headquarters | Plattsburgh, New York AeroChamber2Go® VHC Helps Ensure Kids Can Breathe Easy Anywhere...
A significant, dose-dependent reduction in bone marrow lesion presence and area was observed for LEVI-04 compared with placebo in patients...
This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR")....
image1 VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001 Japanese regulator, the PMDA, waived the...
- Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of...
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 25 September 2025 – 7:00 AM CET Fagron announces the acquisition of...
H1 25 Results Confirm the Relevance of Roquette’s Strategy Roquette outperforms its key markets, delivering solid H1 results in current...
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, September 25, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides...